Lachin 67630-00-6 Tert-butoxicarbonyl-4-NO2-phenylalanine-ethyl ester Manifakti ak faktori |Jiayinglai

67630-00-6 Tert-butoxicarbonyl-4-NO2-phenylalanine-ethyl ester Imaj ki prezante

67630-00-6 Tert-butoxicarbonyl-4-NO2-phenylalanine-etil ester

Deskripsyon kout:

Aparans	Blan ak Off-White kristal oswa poud cristalline.
MF	C16H22N2O6
MW	338.36
Pite	98+

Voye imèl ba nou

Pwodwi detay

Kondisyon transpò ak metòd anbake rekòmande:
pa lè, pa lanmè oswa pa eksprime

Kondisyon depo:
Sele nan sèk, Tanperati chanm

Kantite lòd minimòm:
Negosyasyon

Sètifikasyon:
COA, HPLC, GC, HNMR, Assay, Water Content(KF), TLC disponib

Sinonim

(S) -etil 2-(tèt-butoxicarbonylaMino) -3-(4-nitrofenil) propanoate;
Boc-(4-NO2)-L-Phe-OEt;
Boc-(4-NO2)-Oet;
Boc-Phe(4-NO2)-Oet;
L-fenilalanin;
N-[(1,1-dimethylethoxy)carbonyl]-4-nitro-, ethyl ester

anndan anbalaj

Yo anjeneral yo itilize yo pake poud.Epi yo ka anpeche solèy ak dlo vin move.

anbalaj ekstèn

Katon difisil la ka pwoteje pwodwi ou yo kont ekraze ak mouye.

Aplikasyon

Nidanib, se yon pwodui chimik.Non chimik 1 h - indol - 6 - asid karboksilik, 2, 3 - dihydro - 3 - [[[4 - (methyl [(4 - methyl - 1 - piperazin) asetil] amino] fenil] amino] benzèn heartland nan methyl] - 2 - oksijèn -, methyl ester, (z) - Klinikman, pwodui sa a itilize pou trete fibwoz poumon idiopatik (IPF).
Nidanib te etidye 1,529 pasyan ki gen fibwoz poumon idiopatik (IPF) nan plizyè esè klinik.Done sekirite yo prezante yo baze sou yon konparezon 1061 pasyan yo bay nidanib 150 mg de fwa pa jou ak plasebo nan de 52 semèn faz 3, owaza, doub avèg, syans plasebo-kontwole (INPULSIS-1 ak INPULSIS-2).Evènman negatif ki pi komen ki asosye ak itilizasyon nidanib enkli dyare, kè plen ak vomisman, doulè nan vant, pèt apeti, pèdi pwa, ak anzim fwa ki wo.Tanpri gade nan [Prekosyon] pou jesyon reyaksyon negatif ki koresponn yo.Klasifikasyon Sistematik Ògàn (SOC) MedDRA bay yon rezime reyaksyon negatif ak klasifikasyon frekans yo.
Nidanib se yon substra pou P-gp (gade Farmakokinetik).Nan yon etid espesifik nan entèraksyon dwòg, konbine administrasyon ketoconazole, yon inibitè P-gp pwisan, ogmante ekspoze a nidanib a 1.61 fwa pa zòn anba koub la (AUC) ak 1.83 fwa pa pik konsantrasyon (Cmax).
Nan yon etid entèraksyon dwòg ak P-gp endiktè rifampicin pwisan, ekspoze a nidanib diminye a 50.3%, jan yo mezire pa zòn anba koub la (AUC), lè yo konbine avèk rifampicin konpare ak Nidanib pou kont li.Pa pik konsantrasyon (Cmax), li diminye a 60.3%.
Lè yo administre nan konbinezon ak pwodui sa a, inibitè P-gp pwisan (egzanp, ketoconazole oswa erythromycin) ka ogmante ekspoze a nidanib.Nan ka sa yo, yo ta dwe byen kontwole tolerans pasyan an pou nidanib.Jesyon reyaksyon negatif yo ka mande pou sispann, rediksyon dòz, oswa sispann nan tretman ak pwodui sa a (gade [Itilizasyon ak dòz]).
P-gp pwodiktè ki pisan (egzanp, rifampicin, carbamazepine, fenitoyin ak plan St. John's) ka diminye ekspoze a nidanib.Konbinezon altènatif ki pa gen oswa ki pa gen okenn endiksyon P-gp ta dwe konsidere.

pwodwi ki gen rapò

Gly-Phe	Boc-Phe-Gly-Ome	HN-Me-L-Phe.Hcl	Boc-D-Phe-D-Phe
Boc-D-4-Chloropheny (alanine)	Fmoc-L-Phe-OH	L-Phe-NH2.Hcl	Boc-Phe-Gly
L-Ala-Phe-OH	Fmoc-D-Phe-OH	4-NO2-Phe-Oet	Boc-L-Phe-Onp
Boc-Ala-Phe-OH	Fmoc-N-Me-L-Phe-OH	4-NO2-Phe-Oet.HCl	Boc-L-Phe-Oet
Boc-Ala-Phe-OH	FMOC-N-Me-D-Phe-OH	HD-Phe-OMe·HCl	Boc-4-NO2-D-Phe-OEt
Fmoc-β-Ala-D-phe	Fmoc-Phe-Cl	HL-Phe-OMe.HCl	Boc-D, L-Phe (4-NO2)-OH
Leu-Phe.Hcl	Fmoc-Phe(4-NO2)-OH	H-DL-Phe-OBzl .tos	Fmoc-Phe-Phe-OH
Boc-Leu-Phe	Cbz-L-Phe-OH	H-DL-Phe(4-NO2)-OH.H2O	Fmoc-Phe-Gly-OH
Cbz-L-Phe-Leu-OH	Cbz-D-Phe-OH	HL-Phe-OBzl.HCl	Fmoc-D-Phe(4-NO2)-OH
L-Phe	Cbz-DL-Phe-OH	HL-Phe-OEt.HCl	Cbz-Phe-Arg-OH
HD-Phe-OH	Cbz-D-Phe-OL	L-Phe-NH2	Cbz-Phe-Ala-OH
L-Phe-NCA	ZN-Me-L-Phe-OH	D-Phe-NH2	Cbz-Phe-Gly-OH
Tos-Phe	cbz-L-Phe-OSU	N-Ac-L-Phe-OH	Cbz-Phe-Met-OH
L-Phe-ol	Phe-Ala	N-AC-L-Phe-Ome	Cbz-Phe-Gly-Oet
L-Phe（4-NO2）-OH	L-Phe-Phe	N-Pht-Phe-OH	Boc-Phe-Gly-Gly-OH
L-Phe（4-NO2）.H2O	L-Phe-Trp	Boc-Phe-OH	Fmoc-L-Thr(tBu)-Phe-OH
D-Phe(4-NO2)-OH.h2o	L-Phe-Leu-OH	Boc-D-Phe-OH	D-Phe-NH2
D-Phe(4-NO2)-OH	L-Phe-Tyr-OH	Boc-DL-Phe-OH	Tyr-Phe
N-Me-D-Phe	L-Phe-Gly	BOC-N-Me-D-Phe-OH	DL-Phe-Ome.Hcl
HN-Me-L-Phe-OH	D-Phe-D-Phe	Boc-N-Me-DL-Phe-OH	Boc-Met-Leu-Phe
L-Phe.hcl	L-Phe-OBzl-OH	Boc-N-Me-L-Phe-OH	Asp-Phe-Ome
4-NO2-D-phe.hcl	D-Phe-Obzl.Tos	Boc-N-Me-L-Phe-OH.DCHA	L-Homophe-OH
HL-Phe-OtBu.HCl	Boc-Phe-Ala-OH	Boc-DN-Me-Phe•DCHA	D-Homophe-OH
HD-Phe-OtBu.HCl	Boc-Phe-Leu-OH	Boc-Phe-Ol	L-Homophe-Oet.Hcl
D, L-Phe-OtBu HCl	Boc-Phe-Trp-OH	Boc-D-Phe-Ol	D-Homophe-Oet.HCl
HD-Phe(4-NO2)-Ome.HCl	Boc-L-Phe-Tyr-OH	Boc-Phe-NH2	Boc-L-Homophe-OH
D-Phe-Obzl.Hcl	Boc-Phe-Phe-OH	Boc-L-Phe-Ome	Boc-D-Homophe-OH
DL-Phe-Ome.Hcl	Boc-D-Phe-Phe	Boc-D-Phe-Ome	Fmoc-L-HomoPhe-OH
Boc-D-Phe(4-NO2)-OH	Cbz-D-Homophe-OH	Boc-Phe-Obzl	Fmoc-D-Homophe-OH
Boc-L-Phe-OSU	Boc-Homophe-Leu-Phe-Ome	Boc-4-NO2-Phe-OH	Cbz-L-Homophe-OH
Boc-D-Phe-OSU

Siperyorite

1. R&D sèvis ki disponib
2. ISO sètifye manifakti, garanti bon jan kalite
3.Yon kou konplè nan sèvis swivi pandan pwodiksyon an
4.High pri efikas
5.Dokiman sètifikasyon kalite bay pou chak demann kliyan an
6.Great sèvis apre-lavant, kenbe relasyon sere ak kliyan
7.Full resous pou ede diminye depans anbake yo
8.Free echantiyon yo ofri yo tcheke deyò bon jan kalite anvan nenpòt ki peman
9.Peman tèm negosye
10.Assit kliyan fè fas ak zafè nan Lachin